These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 11734111)

  • 21. Farnesyltransferase inhibitors in breast cancer therapy.
    Dy GK; Adjei AA
    Cancer Invest; 2002; 20 Suppl 2():30-7. PubMed ID: 12442347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting protein prenylation for cancer therapy.
    Berndt N; Hamilton AD; Sebti SM
    Nat Rev Cancer; 2011 Oct; 11(11):775-91. PubMed ID: 22020205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy.
    Sebti SM; Hamilton AD
    Pharmacol Ther; 1997; 74(1):103-14. PubMed ID: 9336018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
    Thomas X; Elhamri M
    Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New targets for therapy in breast cancer: farnesyltransferase inhibitors.
    Head J; Johnston SR
    Breast Cancer Res; 2004; 6(6):262-8. PubMed ID: 15535857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
    Karp JE; Lancet JE
    Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
    Zeng PY; Rane N; Du W; Chintapalli J; Prendergast GC
    Oncogene; 2003 Feb; 22(8):1124-34. PubMed ID: 12606940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibiting Ras signaling in the therapy of breast cancer.
    Li T; Sparano JA
    Clin Breast Cancer; 2003 Feb; 3(6):405-16; discussion 417-20. PubMed ID: 12636885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
    Brunner TB; Hahn SM; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ
    Cancer Res; 2003 Sep; 63(18):5656-68. PubMed ID: 14522880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.
    Santucci R; Mackley PA; Sebti S; Alsina M
    Cancer Control; 2003; 10(5):384-7. PubMed ID: 14581893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
    Caraglia M; Budillon A; Tagliaferri P; Marra M; Abbruzzese A; Caponigro F
    Curr Drug Targets; 2005 May; 6(3):301-23. PubMed ID: 15857290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-clinical development of farnesyltransferase inhibitors.
    Lobell RB; Kohl NE
    Cancer Metastasis Rev; 1998 Jun; 17(2):203-10. PubMed ID: 9770117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
    Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
    Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
    Du W; Lebowitz PF; Prendergast GC
    Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
    O'Regan RM; Khuri FR
    Endocr Relat Cancer; 2004 Jun; 11(2):191-205. PubMed ID: 15163298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein farnesyltransferase inhibitors.
    Ayral-Kaloustian S; Salaski EJ
    Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC; Hamilton AD; Sebti SM
    Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
    de Bono JS; Tolcher AW; Rowinsky EK
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):79-92. PubMed ID: 14613029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.